Breakdown in peripheral tolerance in type 1 diabetes in mice and humans.

Type 1 Diabetes (T1D), also called juvenile diabetes because of its classically early onset, is considered an autoimmune disease targeting the insulin-producing β cells in the pancreatic islets of Langerhans. T1D reflects a loss of tolerance to tissue self-antigens caused by defects in both central tolerance, which aims at eliminating potentially autoreactive lymphocytes developing in the thymus, and peripheral tolerance, which normally controls autoreactive T cells that escaped the thymus. Like in other autoimmune diseases, the mechanisms leading to T1D are multifactorial and depend on a complex combination of genetic, epigenetic, molecular, and cellular elements that result in the breakdown of peripheral tolerance. In this article, we discuss the contribution of these factors in the development of the autoimmune response targeting pancreatic islets in T1D and the therapeutic strategies currently being explored to correct these defects.

[1]  J. Bluestone,et al.  Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells , 2011, The Journal of Immunology.

[2]  Darrell M. Wilson,et al.  Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial , 2011, The Lancet.

[3]  J. Bluestone,et al.  Regulatory T cells: stability revisited. , 2011, Trends in immunology.

[4]  P. Linsley,et al.  miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice , 2011, The Journal of experimental medicine.

[5]  P. Ohashi,et al.  Immunological perspective of self versus tumor antigens: insights from the RIP‐gp model , 2011, Immunological reviews.

[6]  Jonathan H. Esensten,et al.  Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family , 2011, Immunological reviews.

[7]  Jonathan H. Esensten,et al.  Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes , 2011, The Journal of Immunology.

[8]  R. Coffman,et al.  Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. , 2011, Immunity.

[9]  M. Hjorth,et al.  Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial , 2011, Diabetologia.

[10]  C. Goodnow,et al.  Visualizing the Role of Cbl-b in Control of Islet-Reactive CD4 T Cells and Susceptibility to Type 1 Diabetes , 2011, The Journal of Immunology.

[11]  G. Szot,et al.  Islet Transplantation in Type 1 Diabetic Patients Using Calcineurin Inhibitor-Free Immunosuppressive Protocols Based on T-Cell Adhesion or Costimulation Blockade , 2010, Transplantation.

[12]  A. Abbas,et al.  Cutting Edge: Mechanisms of IL-2–Dependent Maintenance of Functional Regulatory T Cells , 2010, The Journal of Immunology.

[13]  Ryan M. O’Connell,et al.  MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. , 2010, Immunity.

[14]  L. Lanier,et al.  Distinct Requirements of MicroRNAs in NK Cell Activation, Survival, and Function , 2010, The Journal of Immunology.

[15]  Christophe Benoist,et al.  Stability of the Regulatory T Cell Lineage in Vivo , 2010, Science.

[16]  David Baltimore,et al.  Function of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 Responses , 2010, Cell.

[17]  M. Atkinson,et al.  Efforts to prevent and halt autoimmune beta cell destruction. , 2010, Endocrinology and metabolism clinics of North America.

[18]  J. Bluestone,et al.  IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells , 2010, The Journal of experimental medicine.

[19]  W. Filipowicz,et al.  Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.

[20]  H. Jalahej,et al.  Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. , 2010, Journal of autoimmunity.

[21]  Nicholas T. Ingolia,et al.  Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.

[22]  M. Peakman,et al.  Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group , 2010, Clinical and experimental immunology.

[23]  J. Bluestone,et al.  Small RNA Regulators of T Cell-Mediated Autoimmunity , 2010, Journal of Clinical Immunology.

[24]  J. Bach,et al.  The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update , 2010, Clinical and experimental immunology.

[25]  Jeffrey A. Bluestone,et al.  Genetics, pathogenesis and clinical interventions in type 1 diabetes , 2010, Nature.

[26]  W. Paul,et al.  Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells , 2010, Science.

[27]  Mark S. Anderson,et al.  AIRE in the thymus and beyond. , 2009, Current opinion in immunology.

[28]  A. Rudensky,et al.  CD4+ Regulatory T Cells Control TH17 Responses in a Stat3-Dependent Manner , 2009, Science.

[29]  K. Cerosaletti,et al.  Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects , 2009, Diabetes.

[30]  C. Benoist,et al.  How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. , 2009, Immunity.

[31]  D. Vignali,et al.  T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. , 2009, Immunity.

[32]  V. Kuchroo,et al.  Genetic Evidence That the Differential Expression of the Ligand-Independent Isoform of CTLA-4 Is the Molecular Basis of the Idd5.1 Type 1 Diabetes Region in Nonobese Diabetic Mice1 , 2009, The Journal of Immunology.

[33]  J. Bluestone,et al.  Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo , 2009, Nature Immunology.

[34]  A. Ziegler,et al.  No Effect of the Altered Peptide Ligand NBI-6024 on β-Cell Residual Function and Insulin Needs in New-Onset Type 1 Diabetes , 2009, Diabetes Care.

[35]  M. Foss,et al.  Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. , 2009, JAMA.

[36]  W. Hagopian,et al.  Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. , 2009, Clinical immunology.

[37]  S. Turley,et al.  Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes , 2009, Nature Immunology.

[38]  Jonathan H. Esensten,et al.  T-bet-Deficient NOD Mice Are Protected from Diabetes Due to Defects in Both T Cell and Innate Immune System Function1 , 2009, The Journal of Immunology.

[39]  K. Murphy,et al.  BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice , 2009, Journal of leukocyte biology.

[40]  L. Bradley Faculty Opinions recommendation of The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. , 2009 .

[41]  D. Littman,et al.  Plasticity of CD4+ T cell lineage differentiation. , 2009, Immunity.

[42]  J. Ludvigsson Therapy with GAD in diabetes , 2009, Diabetes/metabolism research and reviews.

[43]  J. Bluestone,et al.  Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells , 2009, Immunological reviews.

[44]  Å. Lernmark,et al.  GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes , 2009, Diabetologia.

[45]  M. Foss,et al.  C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. , 2009, JAMA.

[46]  G. Kollias,et al.  Cutting Edge: A Critical Role of B and T Lymphocyte Attenuator in Peripheral T Cell Tolerance Induction 1 , 2009, The Journal of Immunology.

[47]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[48]  D. Bending,et al.  Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. , 2009, The Journal of clinical investigation.

[49]  G. Szot,et al.  Expansion of Human Regulatory T-Cells From Patients With Type 1 Diabetes , 2009, Diabetes.

[50]  A. Keegan Faculty Opinions recommendation of Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. , 2009 .

[51]  F. Wong,et al.  Proinsulin peptide immunotherapy in type 1 diabetes: report of a first‐in‐man Phase I safety study , 2009, Clinical and experimental immunology.

[52]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[53]  Hana Lee,et al.  Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. , 2009, Immunity.

[54]  Klaus Rajewsky,et al.  MicroRNA Control in the Immune System: Basic Principles , 2009, Cell.

[55]  Yi-hong Wang,et al.  Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells , 2009, European journal of immunology.

[56]  B. Hering,et al.  2008 Update From the Collaborative Islet Transplant Registry , 2008, Transplantation.

[57]  C. Benoist,et al.  The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors , 2008, Proceedings of the National Academy of Sciences.

[58]  Y. Nikitin,et al.  Association of the T-cell Regulatory Ggene CTLA-4 with Suscep-tibility to Autoimmune Thyroid Disease in Population of Novosibirsk , 2008 .

[59]  H. Siljander,et al.  Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial , 2008, The Lancet.

[60]  J. Buckner,et al.  The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells1 , 2008, The Journal of Immunology.

[61]  Johnny Ludvigsson,et al.  GAD treatment and insulin secretion in recent-onset type 1 diabetes. , 2008, The New England journal of medicine.

[62]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[63]  J. Neu,et al.  The “Perfect Storm” for Type 1 Diabetes , 2008, Diabetes.

[64]  J. Bluestone,et al.  The Effect of Costimulatory and Interleukin 2 Receptor Blockade on Regulatory T Cells in Renal Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[65]  Aaron J. Martin,et al.  ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms , 2008, Proceedings of the National Academy of Sciences.

[66]  E. Wherry,et al.  MyD88 Plays a Critical T Cell-Intrinsic Role in Supporting CD8 T Cell Expansion during Acute Lymphocytic Choriomeningitis Virus Infection1 , 2008, The Journal of Immunology.

[67]  N. Rajewsky,et al.  Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.

[68]  D. Bartel,et al.  The impact of microRNAs on protein output , 2008, Nature.

[69]  R. Ley,et al.  Innate immunity and intestinal microbiota in the development of Type 1 diabetes , 2008, Nature.

[70]  Michael T. McManus,et al.  Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity , 2008, The Journal of experimental medicine.

[71]  A. Rudensky,et al.  Dicer-dependent microRNA pathway safeguards regulatory T cell function , 2008, The Journal of experimental medicine.

[72]  A. Rudensky,et al.  The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease , 2008, The Journal of experimental medicine.

[73]  A. DeFranco,et al.  Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. , 2008, Immunity.

[74]  Howard Y. Chang,et al.  Deletional Tolerance Mediated by Extrathymic Aire-Expressing Cells , 2008, Science.

[75]  J. Bluestone,et al.  Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.

[76]  J. Bluestone,et al.  Spontaneous Development of a Pancreatic Exocrine Disease in CD28-Deficient NOD Mice1 , 2008, The Journal of Immunology.

[77]  J. Bluestone,et al.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.

[78]  N. Rajewsky,et al.  Dicer Ablation Affects Antibody Diversity and Cell Survival in the B Lymphocyte Lineage , 2008, Cell.

[79]  Qizhi Tang,et al.  The Foxp3+ regulatory T cell: a jack of all trades, master of regulation , 2008, Nature Immunology.

[80]  G. Eisenbarth,et al.  Insulin as an autoantigen in NOD/human diabetes. , 2008, Current opinion in immunology.

[81]  M. Atkinson,et al.  Murine Antithymocyte Globulin Therapy Alters Disease Progression in NOD Mice by a Time-Dependent Induction of Immunoregulation , 2008, Diabetes.

[82]  J. Bluestone,et al.  Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. , 2007, Endocrinology.

[83]  S. Miller,et al.  Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease , 2007, Nature Reviews Immunology.

[84]  Y. Belkaid,et al.  A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β– and retinoic acid–dependent mechanism , 2007, The Journal of experimental medicine.

[85]  J. Bluestone,et al.  Constitutive Expression of B7-1 on B Cells Uncovers Autoimmunity toward the B Cell Compartment in the Nonobese Diabetic Mouse1 , 2007, The Journal of Immunology.

[86]  R. A. Bailey,et al.  Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes , 2007, Nature Genetics.

[87]  O. B. O. T. I. Group,et al.  Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study , 2007, Diabetologia.

[88]  N. Rajewsky,et al.  Regulation of the Germinal Center Response by MicroRNA-155 , 2007, Science.

[89]  Anton J. Enright,et al.  Requirement of bic/microRNA-155 for Normal Immune Function , 2007, Science.

[90]  J. Bluestone,et al.  Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment , 2007, Proceedings of the National Academy of Sciences.

[91]  J. Rogers,et al.  Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity , 2007, Nature Genetics.

[92]  A. Rudensky,et al.  Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells , 2007, Nature.

[93]  Ernest Fraenkel,et al.  Foxp3 occupancy and regulation of key target genes during T-cell stimulation , 2007, Nature.

[94]  Vincent C. Manganiello,et al.  Foxp3-dependent programme of regulatory T-cell differentiation , 2007, Nature.

[95]  A. Rudensky,et al.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.

[96]  S. Turley,et al.  Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self , 2007, Nature Immunology.

[97]  J. Bluestone,et al.  Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway , 2006, The Journal of experimental medicine.

[98]  L. Turka,et al.  The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. , 2006, Immunity.

[99]  F. J. Livesey,et al.  A role for Dicer in immune regulation , 2006, The Journal of experimental medicine.

[100]  H. Takada,et al.  Phenotypic and genetic analyses of T‐cell‐mediated immunoregulation in patients with Type 1 diabetes , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[101]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[102]  R. Locksley,et al.  Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. , 2006, The Journal of clinical investigation.

[103]  Katharina Fleischhauer,et al.  Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans , 2006, Immunological reviews.

[104]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[105]  T. Maki,et al.  Short administration of polyclonal anti-T cell antibody (ALS) in NOD mice with extensive insulitis prevents subsequent development of autoimmune diabetes. , 2006, Journal of autoimmunity.

[106]  J. Bluestone,et al.  Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. , 2006, The Journal of clinical investigation.

[107]  A. Sharpe,et al.  Tissue expression of PD-L1 mediates peripheral T cell tolerance , 2006, The Journal of experimental medicine.

[108]  R. Maki,et al.  Immunomodulation in Type 1 Diabetes by NBI‐6024, an Altered Peptide Ligand of the Insulin B(9−23) Epitope , 2006, Scandinavian journal of immunology.

[109]  C. Benoist,et al.  Endocrine self and gut non-self intersect in the pancreatic lymph nodes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[110]  Nunzio Bottini,et al.  Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant , 2005, Nature Genetics.

[111]  A. Rudensky,et al.  A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.

[112]  C. Benoist,et al.  How defects in central tolerance impinge on a deficiency in regulatory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[113]  B. Bisikirska,et al.  TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. , 2005, The Journal of clinical investigation.

[114]  Å. Lernmark,et al.  Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. , 2005, Journal of diabetes and its complications.

[115]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[116]  D. Harlan,et al.  A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.

[117]  N. Brockdorff,et al.  T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer , 2005, The Journal of experimental medicine.

[118]  Adrian Vella,et al.  Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. , 2005, American journal of human genetics.

[119]  L. Chatenoud,et al.  Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. , 2005, Diabetes.

[120]  S. Hori,et al.  Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization , 2005, The Journal of experimental medicine.

[121]  J. Castle,et al.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.

[122]  M. Atkinson,et al.  Presence of Diabetes-Inhibiting, Glutamic Acid Decarboxylase-Specific, IL-10-Dependent, Regulatory T Cells in Naive Nonobese Diabetic Mice1 , 2004, The Journal of Immunology.

[123]  P. Raskin,et al.  Oral Insulin Therapy to Prevent Progression of Immune‐Mediated (Type 1) Diabetes , 2004, Annals of the New York Academy of Sciences.

[124]  D. Moskophidis,et al.  TCR affinity and negative regulation limit autoimmunity , 2004, Nature Medicine.

[125]  C. Janeway,et al.  Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. , 2004, Diabetes.

[126]  G. Szot,et al.  Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. , 2004, The Journal of clinical investigation.

[127]  J. Habener,et al.  Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. , 2004, Diabetes.

[128]  A. Abbas,et al.  Cooperative Roles of CTLA-4 and Regulatory T Cells in Tolerance to an Islet Cell Antigen , 2004, The Journal of experimental medicine.

[129]  Jeffrey A. Bluestone,et al.  In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[130]  Nunzio Bottini,et al.  A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes , 2004, Nature Genetics.

[131]  Mark Peakman,et al.  Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. , 2004, The Journal of clinical investigation.

[132]  S. Husby,et al.  Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. , 2003, Tissue antigens.

[133]  C. Benoist,et al.  Physiological β Cell Death Triggers Priming of Self-reactive T Cells by Dendritic Cells in a Type-1 Diabetes Model , 2003, The Journal of experimental medicine.

[134]  S. Lieberman,et al.  A comprehensive guide to antibody and T-cell responses in type 1 diabetes. , 2003, Tissue antigens.

[135]  V. Kuchroo,et al.  Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance , 2003, Nature Immunology.

[136]  J. Bluestone,et al.  TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes , 2003, Nature Medicine.

[137]  J. Allison,et al.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.

[138]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[139]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[140]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[141]  J. Bluestone,et al.  Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala) , 2003 .

[142]  A. Abbas,et al.  CTLA-4 Differentially Regulates T Cell Responses to Endogenous Tissue Protein Versus Exogenous Immunogen1 , 2002, The Journal of Immunology.

[143]  A. Abbas,et al.  Functional Tolerance is Maintained Despite Proliferation of CD4 T Cells after Encounter with Tissue-derived Antigen , 2002, Developmental immunology.

[144]  T. Malek,et al.  CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. , 2002, Immunity.

[145]  D. Harlan,et al.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[146]  D. Halbert,et al.  T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. , 2002, Cellular immunology.

[147]  Tatyana Chernova,et al.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.

[148]  H. Weiner Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. , 2001, Microbes and infection.

[149]  H. Weiner The mucosal milieu creates tolerogenic dendritic cells and TR1 and TH3 regulatory cells , 2001, Nature Immunology.

[150]  W. Suarez-Pinzon,et al.  Th1 to Th2 Cytokine Shifts in Nonobese Diabetic Mice: Sometimes an Outcome, Rather Than the Cause, of Diabetes Resistance Elicited by Immunostimulation1 , 2001, The Journal of Immunology.

[151]  C. Benoist,et al.  Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[152]  S. Tafuro,et al.  Progression of autoimmune diabetes driven by avidity maturation of a T-cell population , 2000, Nature.

[153]  C. Boitard,et al.  Oral insulin administration and residual (β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial , 2000, The Lancet.

[154]  J. Bluestone,et al.  Blockade of T Cell Activation Using a Surface-Linked Single-Chain Antibody to CTLA-4 (CD152)1 , 2000, The Journal of Immunology.

[155]  J. Bluestone,et al.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.

[156]  J. Todd,et al.  Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping. , 2000, Genome research.

[157]  A. Strasser,et al.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.

[158]  H. Chase,et al.  Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. , 1999, Diabetes care.

[159]  P. Pandolfi,et al.  Impaired Fas response and autoimmunity in Pten+/- mice. , 1999, Science.

[160]  J. Elliott,et al.  Effect of Bacille Calmette-Guérin Vaccination on C-Peptide Secretion in Children Newly Diagnosed With IDDM , 1998, Diabetes Care.

[161]  C. Benoist,et al.  Interleukin-4 Deficiency Does Not Exacerbate Disease in NOD Mice , 1998, Diabetes.

[162]  J. Bluestone,et al.  Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. , 1998, Journal of immunology.

[163]  D. Godfrey,et al.  α/β–T Cell Receptor (TCR)+CD4−CD8− (NKT) Thymocytes Prevent Insulin-dependent Diabetes Mellitus in Nonobese Diabetic (NOD)/Lt Mice by the Influence of Interleukin (IL)-4 and/or IL-10 , 1998, The Journal of experimental medicine.

[164]  C. Benoist,et al.  Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes , 1998, The Journal of experimental medicine.

[165]  C. Thivolet,et al.  Protection Against Autoimmune Diabetes With Oral Insulin Is Associated With the Presence of IL-4 Type 2 T-Cells in the Pancreas and Pancreatic lymph Nodes , 1998, Diabetes.

[166]  Irun R Cohen,et al.  Hsp60 Peptide Therapy of NOD Mouse Diabetes Induces a Th2 Cytokine Burst and Downregulates Autoimmunity to Various β-Cell Antigens , 1997, Diabetes.

[167]  J. Bluestone,et al.  Nonmitogenic Anti-CD3 Monoclonal Antibodies Deliver a Partial T Cell Receptor Signal and Induce Clonal Anergy , 1997, The Journal of experimental medicine.

[168]  L. Chatenoud,et al.  CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. , 1997, Journal of immunology.

[169]  J. Danska,et al.  IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. , 1997, Journal of immunology.

[170]  Camillo Ricordi,et al.  The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes , 1997, Nature Genetics.

[171]  M. V. von Herrath,et al.  Interferon-γ Is Essential for Destruction of β Cells and Development of Insulin-dependent Diabetes Mellitus , 1997, The Journal of experimental medicine.

[172]  E. Fuchs,et al.  CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. , 1996, Immunity.

[173]  N. Sarvetnick,et al.  Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice , 1996, The Journal of experimental medicine.

[174]  Xiaojian Huang,et al.  Genetic Absence of γ-Interferon Delays but Does Not Prevent Diabetes in NOD Mice , 1996, Diabetes.

[175]  M. Atkinson,et al.  Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes , 1996, The Journal of experimental medicine.

[176]  J. Todd,et al.  Resistance alleles at two non-major histocompatibility complex-linked insulin-dependent diabetes loci on chromosome 3, Idd3 and Idd10, protect nonobese diabetic mice from diabetes , 1994, The Journal of experimental medicine.

[177]  L. Chatenoud,et al.  Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[178]  A Jaramillo,et al.  Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice , 1993, The Journal of experimental medicine.

[179]  A. Signore,et al.  NOD mouse colonies around the world--recent facts and figures. , 1993, Immunology today.

[180]  S. Pek,et al.  Prevention of Insulitis and Diabetes Onset by Treatment With Complete Freund's Adjuvant in NOD Mice , 1991, Diabetes.

[181]  P. Bedossa,et al.  Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. , 1991, Journal of autoimmunity.

[182]  M. Sadelain,et al.  Prevention of Type I Diabetes in NOD Mice by Adjuvant Immunotherapy , 1990, Diabetes.

[183]  M. V. von Herrath,et al.  Type 1 diabetes: etiology, immunology, and therapeutic strategies. , 2011, Physiological reviews.

[184]  J. Michálek,et al.  microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. , 2010, Cellular immunology.

[185]  J. Stockman Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomized controlled trial , 2010 .

[186]  E. Vigorito,et al.  Regulatory T Cells Contributes to the Development of Cutting Edge: The Foxp3 Target miR-155 , 2009 .

[187]  Pau Serra,et al.  Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice , 2006, Nature Immunology.

[188]  Mark S. Anderson,et al.  The NOD mouse: a model of immune dysregulation. , 2005, Annual review of immunology.

[189]  P. Novota,et al.  Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. , 2004, The review of diabetic studies : RDS.

[190]  Ray H. Baughman,et al.  Supporting Online Material , 2003 .

[191]  H. Ochs,et al.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 , 2001, Nature Genetics.

[192]  C. Boitard,et al.  Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. , 2000, Lancet.

[193]  M. Oldstone,et al.  Interferon-g Is Essential for Destruction of b Cells and Development of Insulin-dependent Diabetes Mellitus , 1997 .